Russia has been making strong claims by deeming Sputnik V as the first registered coronavirus (COVID-19) vaccine. However, the Union Health Ministry of India has denied Moscow’s claims about collaboration. As such, Russia is in talks to conduct phase 3 trials in different countries including India. The Gamaleya Research Institute and the Russia Defence Ministry are gaining recognition in the global respiratory virus vaccines market since President Putin announced the approval for Sputnik V coronavirus vaccine.
However, the Sputnik V vaccine is under scrutiny since phase 1 clinical trials of the Russian vaccine have not been published in the scientific literature. However, phase 2 trials of Russian vaccine involved several civilians and military volunteers. Thus, researchers and scientists in the Russia respiratory virus vaccines market are focusing on the final stage of testing for Sputnik V vaccine, which will involve the participation of a large number of volunteers.
Apart from Russia, the Serum Institute of India is being highly publicized for developing billions of COVID-19 vaccine doses. Chief executive officer Adar Poonawalla is gaining popularity around the world as the vaccine vanguard, since its facilities have the capacity to produce billions of doses per year. Thus, companies in the respiratory virus vaccines market are taking cues from the largest producers of vaccine in the world to brew the raw materials necessary to experiment with coronavirus vaccines. As such, analysts at Transparency Market Research opine that the COVID-19 vaccine will be ready for deployment worldwide at the earliest by 2022.
Companies in the respiratory virus vaccines market are joining forces with leading biotechnology firms to progress in the pre-clinical test phase. Since the Coronavirus strain is similar to the previous SARS virus, it is potentially easier for scientists to advance in the pre-clinical test phases.
The National Institute of Allergy and Infectious Diseases (NIAID) has announced to provide a funding of ~US$ 51 Mn for the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, in an effort to develop long-lasting influenza vaccines. Thus, research centers in the respiratory virus vaccines market are increasing efforts to set up collaborative research teams that develop more durable and broadly protective influenza vaccines. Constructive efforts by scientists and research centers are bolstering the respiratory virus vaccines market, which is anticipated to advance at a steady CAGR of ~8% during the assessment period.
There is a growing need to effectively fight off influenza on the global level. Hence, pharmaceutical companies are increasing their R&D capabilities to innovate in improved formulations for respiratory virus vaccines.
The World Health Organization (WHO) claims that immunization has become an important tool for innovation in measles vaccines. With the help of immunization, several million infants are being vaccinated against measles, thus lowering mortality rates worldwide. Companies in the respiratory virus vaccines market are developing promising vaccines that protect the health of individuals from tuberculosis and influenza. They are intensifying their R&D capabilities to develop neutralizing antibodies and therapeutic respiratory virus vaccines that can generate value-grab opportunities for manufacturers.
There is a growing demand for needle-free vaccine administration to suit the needs of adolescents, pregnant women, and other age groups. Moreover, there is a need for robust vaccine storage and supply chains that hold promising potentials to transform immunization programs in the upcoming decade. Thus, timely access to reliable data is found to provide exciting opportunities for companies in the respiratory virus vaccines market.
A research done by Emory Vaccine Center and the Centers for Disease Control and Prevention indicates that immunity against mumps virus appears to be insufficient among a fraction of college-aged individuals who were previously vaccinated in their childhood. Thus, companies in the respiratory virus vaccines market are increasing efforts to better understand the immune response to mumps and mumps vaccines. In the past decade, it has been observed that several mumps outbreaks have occurred among sports teams, college students, and close-knit communities in the U.S. Hence, pharmaceutical companies are focusing on developing effective mumps vaccines to lower the rate of mumps outbreaks.
Lack of strong immune response pertaining to mumps vaccine has emerged as a challenge for companies in the respiratory virus vaccines market. Manufacturers are directing large investment in clinical trials to demonstrate the safety and efficacy of mumps vaccines.
Mycobacterium tuberculosis (Mtb) is responsible for high mortality rates, which is the highest among any single infectious pathogen worldwide. Hence, there is a demand for tuberculosis vaccines, since Bacille Calmette Guerin (BCG) is the only licensed vaccine, which is approaching its centenary. Moreover, the BCG vaccine if found to offer little to no protection against adult-type pulmonary tuberculosis. This has created a scope for companies in the respiratory virus vaccines market who can innovate in new TB vaccines.
Pharmaceutical companies are following the Preferred Product Characteristics (PPC) developed by the WHO to identify target populations who can be promising candidates for steering innovation in TB vaccines. These involve the participation of adults, adolescents, and infants. Companies are focusing on developing new TB vaccines for use in mass campaigns that are efficacious in preventing TB among adults and adolescents.
Analysts’ Viewpoint
France’s Pasteur Institute is increasing its R&D activities to use modified measles vaccine to trick the body into producing antibodies that are capable of fighting COVID-19 pathogens. Since seasonal influenza leads to hospitalization of tens of thousands of individuals in the U.S., companies in the respiratory virus vaccines market are tapping into growth opportunities in this domain. However, it is found that the circulating strain has drifted away from the strain that is in the mumps vaccine, which has led to mumps outbreaks among college institutes in the U.S. Hence, companies should invest in clinical trials to generate the desired immune response among individuals.
Respiratory Virus Vaccines Market – Segmentation
|
Type |
|
|
Route of Administration |
|
|
Indication |
|
|
Age Group |
|
|
End User |
|
|
Region |
|
Respiratory virus vaccines market to reach valuation of US$ 14.8 Bn by 2030
Respiratory virus vaccines market is anticipated to expand at a CAGR of ~8% from 2020 to 2030
Respiratory virus vaccines market is driven by rise in prevalence of respiratory illnesses and demand for newer vaccines for the prevention of respiratory infections
The inactivated/killed vaccines segment accounted for a prominent share of the global respiratory virus vaccines market
Key players in the global respiratory virus vaccines market include CSL Limited, Sanofi, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline plc
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Respiratory Virus Vaccines Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Respiratory Virus Vaccines Market Analysis and Forecast, 2018–2030
5. Market Outlook
5.1. Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.)
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Pipeline Analysis
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/Mid-/Long-term Impact) Pricing Analysis
6. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type
6.1. Introduction & Definition
6.2. Global Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030
6.2.1. Inactivated/Killed Vaccines
6.2.2. Live-attenuated Vaccines
6.2.3. Recombinant vaccines
6.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Type
7. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Global Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030
7.2.1. Intramuscular
7.2.2. Intranasal
7.2.3. Subcutaneous
7.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration
8. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication
8.1. Global Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
8.1.1. Influenza
8.1.2. Measles, Mumps & Rubella
8.1.3. Coronavirus Disease (COVID-19)
8.1.4. Others
8.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication
9. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group
9.1. Global Respiratory Virus Vaccines Market Value Forecast, by Age Group, 2018–2030
9.1.1. Pediatric
9.1.2. Adults
9.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group
10. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user
10.1. Global Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030
10.1.1. Physician’s Office
10.1.2. Hospitals
10.1.3. Clinics
10.1.4. Pharmacy/Store
10.1.5. Others
10.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user
11. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Region
11.1. Introduction
11.2. Global Respiratory Virus Vaccines Market Value Forecast, by Region, 2018–2030
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Region
12. North America Respiratory Virus Vaccines Market Analysis and Forecast
12.1. Introduction
12.2. North America Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030
12.2.1. Inactivated/Killed Vaccines
12.2.2. Live-attenuated Vaccines
12.2.3. Recombinant vaccines
12.3. North America Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030
12.3.1. Intramuscular
12.3.2. Intranasal
12.3.3. Subcutaneous
12.4. North America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
12.4.1. Influenza
12.4.2. Measles, Mumps & Rubella
12.4.3. Coronavirus Disease (COVID-19)
12.4.4. Others
12.5. North America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
12.5.1. Pediatric
12.5.2. Adults
12.6. North America Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030
12.6.1. Physician Offices
12.6.2. Hospitals
12.6.3. Clinics
12.6.4. Pharmacy/Store
12.6.5. Others
12.7. North America Respiratory Virus Vaccines Market Value Forecast, by Country, 2018–2030
12.7.1. U.S.
12.7.2. Canada
12.8. North America Respiratory Virus Vaccines Market Attractiveness Analysis
12.8.1. By Type
12.8.2. By Route of Administration
12.8.3. By Indication
12.8.4. By Age Group
12.8.5. By End-user
12.8.6. By Country
13. Europe Respiratory Virus Vaccines Market Analysis and Forecast
13.1. Introduction
13.2. Europe Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030
13.2.1. Inactivated/Killed Vaccines
13.2.2. Live-attenuated Vaccines
13.2.3. Recombinant vaccines
13.3. Europe Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030
13.3.1. Intramuscular
13.3.2. Intranasal
13.3.3. Subcutaneous
13.4. Europe Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
13.4.1. Influenza
13.4.2. Measles, Mumps & Rubella
13.4.3. Coronavirus Disease (COVID-19)
13.4.4. Others
13.5. Europe Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
13.5.1. Pediatric
13.5.2. Adults
13.6. Europe Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030
13.6.1. Physician Offices
13.6.2. Hospitals
13.6.3. Clinics
13.6.4. Pharmacy/Store
13.6.5. Others
13.7. Europe Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Europe Respiratory Virus Vaccines Market Attractiveness Analysis
13.8.1. By Type
13.8.2. By Route of Administration
13.8.3. By Indication
13.8.4. By Age Group
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Respiratory Virus Vaccines Market Analysis and Forecast
14.1. Introduction
14.2. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030
14.2.1. Inactivated/Killed Vaccines
14.2.2. Live-attenuated Vaccines
14.2.3. Recombinant vaccines
14.3. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030
14.3.1. Intramuscular
14.3.2. Intranasal
14.3.3. Subcutaneous
14.4. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
14.4.1. Influenza
14.4.2. Measles, Mumps & Rubella
14.4.3. Coronavirus Disease (COVID-19)
14.4.4. Others
14.5. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
14.5.1. Pediatric
14.5.2. Adults
14.6. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030
14.6.1. Physician Offices
14.6.2. Hospitals
14.6.3. Clinics
14.6.4. Pharmacy/Store
14.6.5. Others
14.7. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030
14.7.1. Japan
14.7.2. China
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis
14.8.1. By Type
14.8.2. By Route of Administration
14.8.3. By Indication
14.8.4. By Age Group
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Respiratory Virus Vaccines Market Analysis and Forecast
15.1. Introduction
15.2. Latin America Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030
15.2.1. Inactivated/Killed Vaccines
15.2.2. Live-attenuated Vaccines
15.2.3. Recombinant vaccines
15.3. Latin America Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030
15.3.1. Intramuscular
15.3.2. Intranasal
15.3.3. Subcutaneous
15.4. Latin America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
15.4.1. Influenza
15.4.2. Measles, Mumps & Rubella
15.4.3. Coronavirus Disease (COVID-19)
15.4.4. Others
15.5. Latin America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
15.5.1. Pediatric
15.5.2. Adults
15.6. Latin America Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030
15.6.1. Physician Offices
15.6.2. Hospitals
15.6.3. Clinics
15.6.4. Pharmacy/Store
15.6.5. Others
15.7. Latin America Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Latin America Respiratory Virus Vaccines Market Attractiveness Analysis
15.8.1. By Type
15.8.2. By Route of Administration
15.8.3. By Indication
15.8.4. By Age Group
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Respiratory Virus Vaccines Market Analysis and Forecast
16.1. Introduction
16.2. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030
16.2.1. Inactivated/Killed Vaccines
16.2.2. Live-attenuated Vaccines
16.2.3. Recombinant vaccines
16.3. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Route of Administration , 2018–2030
16.3.1. Intramuscular
16.3.2. Intranasal
16.3.3. Subcutaneous
16.4. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
16.4.1. Influenza
16.4.2. Measles, Mumps & Rubella
16.4.3. Coronavirus Disease (COVID-19)
16.4.4. Others
16.5. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030
16.5.1. Pediatric
16.5.2. Adults
16.6. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030
16.6.1. Physician Offices
16.6.2. Hospitals
16.6.3. Clinics
16.6.4. Pharmacy/Store
16.6.5. Others
16.7. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis
16.8.1. By Type
16.8.2. By Route of Administration
16.8.3. By Indication
16.8.4. By Age Group
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (by tier and size of companies)
17.2. Global Respiratory Virus Vaccines Market Position Analysis, by Company, 2019
17.3. Company Profiles
17.3.1. CSL Limited
17.3.1.1. Company Description
17.3.1.2. Business Overview
17.3.1.3. Financial Overview
17.3.1.4. Strategic Overview
17.3.1.5. SWOT Analysis
17.3.2. Sanofi
17.3.2.1. Company Description
17.3.2.2. Business Overview
17.3.2.3. Financial Overview
17.3.2.4. Strategic Overview
17.3.2.5. SWOT Analysis
17.3.3. AstraZeneca
17.3.3.1. Company Description
17.3.3.2. Business Overview
17.3.3.3. Financial Overview
17.3.3.4. Strategic Overview
17.3.3.5. SWOT Analysis
17.3.4. Merck & Co., Inc.
17.3.4.1. Company Description
17.3.4.2. Business Overview
17.3.4.3. Strategic Overview
17.3.4.4. Financial Overview
17.3.4.5. SWOT Analysis
17.3.5. GlaxoSmithKline plc
17.3.5.1. Company Description
17.3.5.2. Business Overview
17.3.5.3. Strategic Overview
17.3.5.4. Financial Overview
17.3.5.5. SWOT Analysis
17.3.6. Serum Institute of India Pvt. Ltd.
17.3.6.1. Company Description
17.3.6.2. Business Overview
17.3.6.3. Financial Overview
17.3.6.4. Strategic Overview
17.3.6.5. SWOT Analysis
17.3.7. Bharat Biotech
17.3.7.1. Company Description
17.3.7.2. Business Overview
17.3.7.3. Financial Overview
17.3.7.4. Strategic Overview
17.3.7.5. SWOT Analysis
17.3.8. Sinovac Biotech Ltd.
17.3.8.1. Company Description
17.3.8.2. Business Overview
17.3.8.3. Financial Overview
17.3.8.4. Strategic Overview
17.3.8.5. SWOT Analysis
List of Tables:
Table 01 Pipeline Analysis (1/4)
Table 02 Pipeline Analysis (2/4)
Table 03 Pipeline Analysis (3/4)
Table 04 Pipeline Analysis (4/4)
Table 05 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (1/3)
Table 06 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (2/3)
Table 07 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (3/3)
Table 08 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 09 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 10 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 11 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030
Table 12 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 13 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 14 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 15 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 16 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 17 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 18 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030
Table 19 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 20 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 21 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 22 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 23 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 24 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030
Table 25 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 26 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 27 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 28 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 29 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 30 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030
Table 31 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 32 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 33 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 34 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 35 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 36 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030
Table 37 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 38 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 39 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 40 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 41 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 42 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030
Table 43 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030
List of Figures:
Figure 01 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
Figure 02 Global Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
Figure 03 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
Figure 04 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Inactivated/Killed Vaccines, 2018-2030
Figure 05 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Live-attenuated Vaccines, 2018-2030
Figure 06 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Recombinant vaccines, 2018-2030
Figure 07 Global Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 08 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
Figure 09 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Intramuscular, 2018-2030
Figure 10 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Intranasal, 2018-2030
Figure 11 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous, 2018-2030
Figure 12 Global Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
Figure 13 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
Figure 14 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Influenza, 2018-2030
Figure 15 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Measles, Mumps & Rubella, 2018-2030
Figure 16 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Coronavirus Disease (COVID-19), 2018-2030
Figure 17 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2030
Figure 18 Global Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
Figure 19 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
Figure 20 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Pediatric, 2018-2030
Figure 21 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Adult, 2018-2030
Figure 22 Global Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
Figure 23 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
Figure 24 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Physician Offices, 2018-2030
Figure 25 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2018-2030
Figure 26 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2018-2030
Figure 27 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Pharmacy/Store, 2018-2030
Figure 28 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2030
Figure 29 Global Respiratory Virus Vaccines Market Value Share Analysis, by Region, 2019 and 2030
Figure 30 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Region, 2020-2030
Figure 31 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
Figure 32 North America Respiratory Virus Vaccines Market Value Share Analysis, by Country, 2019 and 2030
Figure 33 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Country, 2020-2030
Figure 34 North America Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
Figure 35 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
Figure 36 North America Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 37 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
Figure 38 North America Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
Figure 39 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
Figure 40 North America Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
Figure 41 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
Figure 42 North America Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
Figure 43 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
Figure 44 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
Figure 45 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 46 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Country, 2020-2030
Figure 47 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
Figure 48 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
Figure 49 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 50 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
Figure 51 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
Figure 52 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
Figure 53 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
Figure 54 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
Figure 55 Europe Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
Figure 56 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
Figure 57 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
Figure 58 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 59 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
Figure 60 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
Figure 61 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
Figure 62 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 63 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
Figure 64 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
Figure 65 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
Figure 66 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
Figure 67 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
Figure 68 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
Figure 69 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
Figure 70 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
Figure 71 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 72 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
Figure 73 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
Figure 74 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
Figure 75 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 76 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
Figure 77 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
Figure 78 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
Figure 79 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
Figure 80 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
Figure 81 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
Figure 82 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
Figure 83 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030
Figure 84 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 85 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
Figure 86 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030
Figure 87 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030
Figure 88 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 89 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030
Figure 90 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030
Figure 91 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030
Figure 92 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030
Figure 93 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030
Figure 94 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030
Figure 95 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Respiratory Virus Vaccines Market
